{"title":"Lutein, a non-provitamin A carotenoid, reduces cisplatin-induced cardiotoxicity.","authors":"Fatih Mehmet Gür, Sedat Bilgiç, İbrahim Aktaş","doi":"10.1016/j.prostaglandins.2025.106965","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular complications resulting from cisplatin (CS) are a significant factor that can disrupt the treatment plan associated with this chemotherapy. This information led us to investigate the effectiveness of lutein (LT), which has antioxidant effects, in preventing CS-induced cardiotoxic effects. After 28 rats were randomly divided into four equal groups, saline (1 ml/day) was administered to the control group, LT (100 mg/kg/day) to the LT group, CS (10 mg/kg) to the CS group, and active agents in the LT and CS groups were administered to the CS + LT group in the same dose and manner. The examinations determined that MDA, cardiac biomarkers (CK-MB, BNP, LDH, and cTn-I) levels, TNF-α and caspase-3 expressions, and apoptosis significantly increased in the CS group. In contrast, GSH, SOD, and CAT levels were decreased. In addition, histopathological changes characterized by interstitial edema, leukocyte infiltration, and vacuolar degeneration were detected in the heart tissues of this group. It was determined that LT application prevented the above-mentioned CS-induced cardiotoxic effects to a significant extent, although not completely. The findings obtained in this study show that LT may reduce CS-induced cardiac damage thanks to its ROS-reducing, anti-inflammatory, anti-apoptotic, and cytoprotective characteristics.</p>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":" ","pages":"106965"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins & other lipid mediators","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.prostaglandins.2025.106965","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Cardiovascular complications resulting from cisplatin (CS) are a significant factor that can disrupt the treatment plan associated with this chemotherapy. This information led us to investigate the effectiveness of lutein (LT), which has antioxidant effects, in preventing CS-induced cardiotoxic effects. After 28 rats were randomly divided into four equal groups, saline (1 ml/day) was administered to the control group, LT (100 mg/kg/day) to the LT group, CS (10 mg/kg) to the CS group, and active agents in the LT and CS groups were administered to the CS + LT group in the same dose and manner. The examinations determined that MDA, cardiac biomarkers (CK-MB, BNP, LDH, and cTn-I) levels, TNF-α and caspase-3 expressions, and apoptosis significantly increased in the CS group. In contrast, GSH, SOD, and CAT levels were decreased. In addition, histopathological changes characterized by interstitial edema, leukocyte infiltration, and vacuolar degeneration were detected in the heart tissues of this group. It was determined that LT application prevented the above-mentioned CS-induced cardiotoxic effects to a significant extent, although not completely. The findings obtained in this study show that LT may reduce CS-induced cardiac damage thanks to its ROS-reducing, anti-inflammatory, anti-apoptotic, and cytoprotective characteristics.
期刊介绍:
Prostaglandins & Other Lipid Mediators is the original and foremost journal dealing with prostaglandins and related lipid mediator substances. It includes basic and clinical studies related to the pharmacology, physiology, pathology and biochemistry of lipid mediators.
Prostaglandins & Other Lipid Mediators invites reports of original research, mini-reviews, reviews, and methods articles in the basic and clinical aspects of all areas of lipid mediator research: cell biology, developmental biology, genetics, molecular biology, chemistry, biochemistry, physiology, pharmacology, endocrinology, biology, the medical sciences, and epidemiology.
Prostaglandins & Other Lipid Mediators also accepts proposals for special issue topics. The Editors will make every effort to advise authors of the decision on the submitted manuscript within 3-4 weeks of receipt.